Vicore Pharma Holding AB

NASDAQ:VCRE

Medical - Pharmaceuticals

Healthcare
$9.90 -1.66%

-$0.24 today

Market cap
$279.65M
Beta
0.15

Volume 0.00M

Average 0.26M

VCRE Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Vicore Pharma Holding ABNASDAQ: VCRE

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin holds steady near 100.0%

Gross margin was 100.0% in Q2 FY2026, up 0.0 pp from a year earlier. On a trailing-twelve-month basis it was 100.0%, up 17.9 pp year over year.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
100.0%+0.0 pp QoQ
Last fiscal yearDec 2025
100.0%+0.0 pp YoY
LTMJun 2026
100.0%+17.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.0 pp——
1 year+0.0 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+0.0pp

Gross Margin vs competitors

How VCRE compares with its peers on the latest reported figures

  • VCRE's LTM Jun 2026 gross margin of 100.0% is the highest of the 2 companies compared; the peer median is 92.5%.
  • Its year-over-year change of +17.9 pp is the lowest of 2, against a peer median of +22.1 pp.
VCRE Competitors Peer median
Gross Margin for VCRE and competitors
Company Period LTM level YoY 3-year change
VCREVicore Pharma Holding ABLTM Jun 2026100.0% +17.9 pp—
LQDALiquidia CorporationLTM Jun 202692.5% +22.1 pp+9.6 pp
AVLNAvalyn Pharma Inc. Common Stock—— ——
Peer median (excluding VCRE) 92.5%+22.1 pp+9.6 pp

Competitors are the stored peer set for VCRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

SEK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000109.35M3.82M
Cost of Revenue3.58M0000
Gross Profit(3.58M)00109.35M3.82M
Gross Margin———100.0%100.0%
Research & Development30.05M249.97M276.29M249.26M390.35M
Selling, General & Admin2.39M37.53M44.6M50.44M67.91M
Operating Expenses32.59M290.73M321.51M299.71M458.26M
Depreciation & Amortization371.33K3.61M3.42M2.24M0
EBITDA(32.07M)(285.19M)(307.9M)(166.64M)(477.41M)
EBITDA Margin———-152.4%-12507.6%
Operating Income(32.59M)(290.73M)(321.51M)(190.36M)(454.45M)
Operating Margin———-174.1%-11905.8%
Interest Income70.2K913K10.54M21.08M23.89M
Interest Expense08K2K8K60K
Other Income / Expenses(211.92K)1.92M10.18M21.47M(23.03M)
Income Before Tax(32.8M)(288.81M)(311.33M)(168.89M)(477.47M)
Pre-Tax Margin———-154.5%-12509.1%
Income Tax Expense(252.7K)(384K)(384K)(256K)0
Net Income(294.97M)(288.42M)(310.94M)(168.63M)(477.47M)
Net Margin———-154.2%-12509.1%
EPS (Basic)(0.47)(38.82)(31.80)(12.30)(19.90)
EPS (Diluted)(0.47)(38.82)(31.80)(12.30)(19.90)
Weighted Avg Shares69.68M7.42M9.66M13.68M23.99M
Weighted Avg Shares (Diluted)69.68M7.42M9.66M13.68M23.99M

Vicore Pharma Holding AB

NASDAQ:VCRE

Intrinsic Alpha fair value

Locked

Current Price

$9.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.